Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68071-3779

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3779). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3779 3)

Label for Duloxetine 30 mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label indicates a 30-count package and states each capsule contains 33.7 mg Duloxetine Hydrochloride USP equivalent to 30 mg Duloxetine. It includes manufacturer and packaging information, dosage instructions, and warning to keep out of reach of children.*

FDA Label Image

Figure6 (Image 10)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The y-axis represents the percentage of patients improved from 0 to 100%, and the x-axis denotes percent improvement in pain from baseline, ranging from >0 to 100%. Vertical reference lines are shown at approximately 30% and 50% improvement.*

FDA Label Image

Figure 7 (Image 11)

A line graph showing the percentage of patients improved versus the percent improvement in pain from baseline. It compares Duloxetine delayed-release 60 mg once daily with placebo, illustrating higher patient improvement percentages with Duloxetine across various pain improvement thresholds.*

FDA Label Image

Figure8 (Image 12)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The graph compares placebo and duloxetine delayed-release 60 mg/120 mg once daily, illustrating trends in patient improvement over varying pain reduction percentages.*

FDA Label Image

Figure9 (Image 13)

A line graph comparing the percentage of patients improved over percent improvement in pain from baseline. The graph plots data for Placebo and Duloxetine Delayed-Release 60 mg Once Daily, showing Duloxetine generally leading to higher percentages of patients improved across increasing pain improvement percentages.*

FDA Label Image

Figure10 (Image 14)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline (BOCF). It compares Duloxetine Delayed-Release 60/120 mg once daily and placebo over a range of pain improvement percentages, with Duloxetine showing higher patient improvement across the chart.*

FDA Label Image

Pdp (Image 16)

FDA Label Image

1 (Image 4)

Chemical structure of duloxetine showing the arrangement of atoms including a naphthalene ring, a thiophene ring, and an amine group as part of its molecular formula.*

FDA Label Image

Figure1 (Image 5)

A Kaplan-Meier plot depicting the proportion of patients with relapse over time from randomization to relapse (in days). The graph compares patients treated with Duloxetine delayed-release capsules versus placebo, showing relapse proportions on the y-axis and days on the x-axis.*

FDA Label Image

Figure2 (Image 6)

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time since randomization (in days). It compares Duloxetine delayed-release capsules versus placebo, with the placebo curve showing a higher relapse proportion than the Duloxetine treatment over the observed period up to approximately 250 days.*

FDA Label Image

Figure3 (Image 7)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60mg BID, Duloxetine 60mg QD, Duloxetine 20mg QD, and a placebo, showing trends of patient improvement across different pain reduction thresholds.*

FDA Label Image

Figure4 (Image 8)

A line graph showing the percentage of patients improved based on percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, with data points indicating higher improvement percentages for Duloxetine groups compared to placebo across various percent improvement levels.*

FDA Label Image

Figure5 (Image 9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. The y-axis shows the percentage of patients improved, and the x-axis indicates percent improvement in pain, with curves depicting patient response distributions for the three treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.